TrialRheumatology (Oxford, England)2022

New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension.

John H Stone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.